2월 18일 09:09

Galderma Announces Appointment of New Chief Financial Officer

Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the appointment of Luigi La Corte as Chief Financial Offi ...

제약인사

2월 12일 15:22

We Are All Sculptra: First-of-its-Kind Galderma Initiative to Demonstrate How Everyone Can Benefit from Sculptra’s Regenerative Properties

Galderma (SIX: GALD), the pure-play dermatology category leader, today unveiled We Are All Sculptra, a unique program designed to capture the clin ...

제약판촉

2월 11일 15:13

Galderma Expands Restylane® Portfolio in Japan With Launch of OBT™ Hyaluronic Acid Injectables Restylane Defyne™ and Refyne™

Galderma (SIX: GALD), the pure-play dermatology category leader, has announced the launch of Restylane Defyne and Restylane Refyne: the first OBT ...

제약신상품

2월 2일 15:13

Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission

Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of ...

제약인증

1월 30일 15:34

Galderma Tackles Menopause-related Skin Changes With Global Survey and Clinical Trial Inclusivity

Galderma (SIX: GALD) has unveiled findings from a global survey of peri- and post-menopausal women from nine countries exploring the impact of men ...

제약조사분석

1월 29일 15:24

Galderma Unveils ‘Wake Up To Restylane’, Underscoring Restylane as the Ideal Hyaluronic Acid Treatment for Always-On Natural Beauty

Galderma (SIX: GALD), the pure-play dermatology category leader, has launched ‘Wake Up To Restylane’, a global campaign that showcases Restylane a ...

제약판촉

1월 22일 15:41

IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry’s Broadest Injectable Aesthetics Portfolio

Galderma (SIX: GALD) will present ten posters with the latest updates from across its broad aesthetic portfolio spanning regenerative biostimulation, HA and neuromodu ...

생명공학제약전시

1월 22일 09:16

Galderma Provides Update on Arbitration Case Regarding Neuromodulator Research and Development Partnership

Galderma (SIX:GALD), the pure-play dermatology category leader, today announced that an International Chamber of Commerce arbitral tribunal issued ...

제약회사 공지

1월 14일 16:32

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics

Galderma (SIX: GALD) will present data on its innovative and industry-leading neuromodulator portfolio at the TOXINS 2026 International Conference ...

제약연구개발

2025년 12월 17일 15:45

New Published Data Confirms Nemluvio® (Nemolizumab) Can Rapidly Relieve Itch and Improve Sleep in as Early as Two Days in Both Atopic Dermatitis and Prurigo Nodularis

Galderma (SIX: GALD), the pure-play dermatology category leader, today released new clinical data confirming nemolizumab’s rapid onset of action o ...

제약조사분석

2025년 12월 11일 16:35

Galderma Announces First Patient Enrollment in Study to Assess Nemolizumab in Adults With Chronic Pruritus of Unknown Origin

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the first patient enrollment for its phase II study investigating ...

제약연구개발

2025년 12월 5일 15:40

Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the Europea ...

제약인증

2025년 12월 4일 15:09

Galderma Secures ‘BBB’ Credit Rating With Positive Outlook from S&P Global Ratings

Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that S&P Global Ratings (S&P) has assigned the company a ...

의료기기제약주주

2025년 11월 17일 15:50

ASDS 2025: Compelling New Data on Restylane, Sculptra and Relfydess Highlight Galderma’s Innovative Injectable Aesthetics Portfolio and Pipeline

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it presented new data from its Injectable Aesthetics portfol ...

제약미용조사분석

2025년 9월 24일 16:10

AMWC Dubai: Galderma Demonstrates Injectable Aesthetics Leadership Through Updates on Its Scientific Innovations and Community Education

Galderma will present six posters with the latest updates from its science-backed aesthetic portfolio at the Aesthetic & Anti-Aging Medicine World ...

제약연구개발

2025년 9월 18일 15:34

Galderma Launches Transformative Skincare Segment With Cetaphil’s New Skin Activator Hydrating & Firming Line, in Partnership With Actor and Filmmaker Mariska Hargitay

Galderma today announced Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is redefining daily skincare with ...

미용화장품신상품

2025년 9월 17일 16:10

Galderma’s Groundbreaking Real-World Study Reveals the Biological Toll of Modern Living and Urban Environments on Sensitive Skin

Galderma today announced new data from a first-of-its-kind real-world clinical study conducted in China assessing the biological impact of differe ...

제약연구개발

2025년 9월 11일 15:50

EADV 2025: Galderma Reinforces Leadership in Dermatology With Latest Advances in Sensitive Skin and Itch

Galderma (SIX: GALD), the dermatology category leader, today announced it will unveil updates from its portfolio at the 34th European Academy of D ...

제약연구개발

2025년 9월 10일 16:30

Galderma Launches Alastin® in China, Supporting the Skin’s Natural Regenerative Abilities in a Rapidly Expanding Market

Galderma (SIX: GALD) today announced the launch of four core Alastin® products in China, marking the premium medical skincare brand’s debut in one ...

제약신상품

2025년 7월 24일 14:52

Galderma Delivers Record First Half 2025 Net Sales of 2.448 Billion USD and 12.2% Year-on-Year Growth at Constant Currency, Raises Full-Year Top-Line Guidance

Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the first half of 2025. · Recor ...

제약미용실적

2025년 7월 17일 14:23

Galderma Unveils Final Nine-Month Data Showing Lasting Efficacy and Patient Satisfaction With Its Injectable Aesthetics Portfolio When Addressing Facial Aesthetic Changes After Medication-Driven Weight Loss

Galderma has revealed positive final data from a phase IV first-of-its-kind trial exploring the benefits of Restylane Lyft or Contour in combinati ...

임상시험제약연구개발

2025년 6월 25일 15:00

Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the initiation of two new clinical trials to investigate the effi ...

임상시험제약연구개발

2025년 6월 18일 14:29

ICD 2025: New data demonstrate Nemluvio®’s (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years

Galderma (SIX: GALD) today announced data from a new interim analysis of a study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe pru ...

의학제약연구개발

2025년 6월 8일 11:35

RAD 2025: Long-Term Data on Nemluvio® (nemolizumab) Demonstrate its Favorable Safety Profile and Sustained and Increased Improvements in Itch and Skin Lesions in Patients With Atopic Dermatitis up to Two Years

Galderma (SIX: GALD) today announced two-year data from a new interim analysis of a long-term extension study investigating the safety and efficac ...

제약연구개발

2025년 5월 28일 14:32

Galderma Buys Back Shares Worth CHF 233 Million in the Context of Accelerated Bookbuild Offering

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it has agreed to repurchase 2.38 million shares at a price o ...

제약투자

 전체 기업